Shots:

• The P-III TULIP program involves two P-III trials (TULIP 1 & 2) assessing the efficacy & safety of anifrolumab (150mg/300mg- 300mg- q4w) vs PBO in (457 & 362) patients in ratio (1:2:2) & (1:1) with SLE resectively
• The new post-hoc analysis showed improvements in both skin rash & arthritis across three different disease measures- SLEDAI (13.5% & 8.2%)- BILAG (15.5% & 11.8%) and 15.6% mCLASI for skin rash & 12.6% joint response for arthritis. TULIP-1 did not meet its 1EPs based on the SRI4 composite measure
• The application is under review by regulatory authorities in the US- EU- and Japan- with decisions anticipated in H2’21

  Ref: AstraZeneca | Image: Mint